A nomogram for the prediction of co-infection in MDA5 dermatomyositis: A rapid clinical assessment model
- PMID: 39842682
- DOI: 10.1016/j.clim.2025.110431
A nomogram for the prediction of co-infection in MDA5 dermatomyositis: A rapid clinical assessment model
Abstract
Background: Patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5 DM) are prone to infections, but there is a lack of rapid methods to assess infection risk, which greatly affects patient prognosis. This study aims to analyze the clinical features of MDA5 DM patients systematically and develop a predictive model for infections.
Methods: Retrospective analysis was performed on clinical data from 118 hospitalized patients with MDA5 DM. According to the results of pathogen detection and clinical manifestations, the patients were divided into infected group and non-infected group. LASSO analysis and multivariate logistic regression were used to establish the prediction model of infection in MAD5 DM patients. The resulting model was visualized using a Nomogram. We used methods such as Receiver Operating Characteristic (ROC) curve analysis, Area Under the Curve (AUC) calculation to evaluate the model.
Result: The Cough, interstitial lung disease, moist rales, positive anti-RO-52, carcinoembryonic antigen, triglyceride, hydroxybutyrate dehydrogenase and erythrocyte sedimentation rate were significantly associated with infection risk in MDA5 DM patients. A prediction model was developed using these eight risk factors, achieving an AUC of 0.851 in determining co-infection status. Further analysis based on infection site and pathogen classification demonstrated strong discrimination performance of the model in identifying pulmonary infection (AUC: 0.844) and fungal infection (AUC: 0.822).
Conclusion: This study aimed to develop a clinical prediction model and visualize it using Nomogram to assess the risk of infection in MDA5 DM. The model provides an effective tool for determining infection status in patients and serves as a reference for formulating clinical medication regimens.
Keywords: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (MDA5 DM); Infection; Nomogram; Prediction model.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no competing interests.
Similar articles
-
Clinical features and survival analysis of 40 cases of anti-MDA5 antibody-positive dermatomyositis complicated with interstitial lung disease.Arthritis Res Ther. 2025 Feb 13;27(1):32. doi: 10.1186/s13075-025-03485-z. Arthritis Res Ther. 2025. PMID: 39948593 Free PMC article.
-
The efficacy and safety of tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis.Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241294000. doi: 10.1177/17534666241294000. Ther Adv Respir Dis. 2024. PMID: 39480695 Free PMC article.
-
Severe interstitial lung disease risk prediction in anti-melanoma differentiation-associated protein 5 positive dermatomyositis: the STRAD-Ro52 model.Ann Med. 2025 Dec;57(1):2440621. doi: 10.1080/07853890.2024.2440621. Epub 2024 Dec 19. Ann Med. 2025. PMID: 39697063 Free PMC article.
-
Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.J Rheumatol. 2019 Aug;46(8):935-942. doi: 10.3899/jrheum.180825. Epub 2019 May 15. J Rheumatol. 2019. PMID: 31092718
-
Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.Rheumatol Int. 2019 Nov;39(11):1971-1981. doi: 10.1007/s00296-019-04398-2. Epub 2019 Aug 2. Rheumatol Int. 2019. PMID: 31375890 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials